YOLFTbeta
Optimi Health Corp. Common Shares

Optimi Health Corp. Common Shares

OPTH · NASDAQ · Healthcare / Drug Manufacturers - Specialty & Generic

2.25USD+0.07 (+3.21%)

Price History

Full chart

Market Stats

Previous Close2.18
Open2.17
Day Range2.03 – 2.31
52-Week Range4.00 – 8.84
Volume40.28K
Market Cap27.60M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.42
Dividend Yield0.00%
Beta1.59
50-Day Avg4.83
200-Day Avg4.86

About

Optimi Health Corp. operates as a pharmaceutical and nutraceutical drug manufacturing company in Canada. The company manufactures controlled substances including finished MDMA and psilocybin drug products, supplying them directly to authorized clinics, pharmacies, clinical trials, and partners. The company produces and supplies MDMA, natural psilocybin, psilocin, other psychedelic substances, and functional mushrooms derived from botanical sources for health and wellness markets. The company also engages in farming, processing, and distribution of raw mushroom biomass, mushroom extracts, manufacturing of drug products, and mushroom supplements. It sells its products through Amazon marketplace and distributors/brokers, as well as online. Optimi Health Corp. was incorporated in 2020 and is based in Princeton, Canada.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Dane Stevens
  • Employees6
  • Headquarters269 David Brown Way, Princeton, BC, Canada, V0X 1W0, USA
  • Websitehttps://www.optimihealth.ca

Leadership

  • Mr. John James WilsonCo-Founder & Chairman · b. 1989
  • Mr. Dane StevensCo-Founder, CEO, Chief Marketing Officer & Director · b. 1989
  • Mr. Bryan Edward SafarikCo-Founder, COO & Director · b. 1985
  • Mr. Jacob SafarikInterim CFO & Director · b. 1988
  • Dr. Preston A. ChaseChief Science Officer
  • Ms. Ann LittleHuman Resources Manager

Financials

Income Statement

Currency: CAD2020-09-302021-09-302022-09-302023-09-302024-09-302025-09-30
Total Revenue--80.72K181.09K389.85K426.90K
Growth (%)---+124.35%+115.28%+9.50%
Cost of Revenue5.42K47.12K26.80K338.12K118.94K2.50M
Gross Profit-5.42K-47.12K53.92K-157.04K270.91K-2.08M
Gross Margin--66.80%-86.72%69.49%-486.44%
Operating Expense478.00K6.01M7.44M4.22M5.88M2.46M
Operating Income-483.42K-6.06M-7.39M-4.38M-5.61M-4.53M
Operating Margin---9155.17%-2419.07%-1438.81%-1062.29%
EBITDA-499.69K-5.95M-7.03M-4.42M-4.74M-2.23M
EBITDA Margin---8708.50%-2441.52%-1215.49%-523.11%
Net Income-507.66K-6.02M-7.35M-5.19M-6.04M-3.72M
Net Income Margin---9106.91%-2868.54%-1548.25%-870.75%
R&D-240.92K133.24K152.15K144.47K348.19K
R&D as % of Total Revenue--165.06%84.02%37.06%81.56%
Interest Expense7.91K19.18K27.99K43.71K429.34K532.43K
Interest Expense % of Total Revenue--34.68%24.14%110.13%124.72%

Balance Sheet

Currency: CAD2020-09-302021-09-302022-09-302023-09-302024-09-302025-09-30
Total Assets6.17M23.46M16.82M16.49M14.55M15.23M
Total Liabilities882.66K2.40M797.66K3.28M4.98M8.65M
Total Equity5.29M21.07M16.02M13.21M9.58M6.58M
Cash4.47M8.43M1.89M1.34M103.66K1.14M
Total Debt156.32K250.84K157.58K1.71M2.75M6.69M
Net Debt-4.31M-8.18M-1.73M362.46K2.65M5.55M

Cash Flow

Currency: CAD2020-09-302021-09-302022-09-302023-09-302024-09-302025-09-30
Operating Cash Flow-143.45K-6.02M-4.58M-3.60M-4.28M-2.63M
Investing Cash Flow-754.83K-9.19M-3.15M-706.02K-154.02K-88.38K
Financing Cash Flow5.37M19.18M1.19M3.76M3.19M3.76M
Capital Expenditure754.83K4.94M7.15M804.23K152.39K88.38K
Free Cash Flow-898.27K-10.96M-11.73M-4.41M-4.43M-2.72M
FCF to OCF626.21%181.94%256.16%122.33%103.56%103.36%

Earnings

Report DateJun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Feb 25, 2026Jun 2, 2026Aug 14, 2026Nov 13, 2026
EPS Estimate--------------------0.26-0.29
EPS Actual-0.76-0.96-1.00-0.59-0.41-0.47-0.32-0.31-0.39-0.34-0.32-0.37-0.40-0.40-0.29-0.04-0.20-0.35-0.36-0.40-
Surprise--------------------53.85%-
Timing---------------------

Key Statistics & Ratios

Market Cap27.60M
Enterprise Value22.90M
Trailing P/E0.00
Forward P/E0.00
Price / Sales157.10
Price / Book2.26
EPS-1.42
Book Value2.23
Revenue (TTM)175.67K
Gross Profit (TTM)-308.15K
EBITDA-4.21M
Profit Margin0.00%
Operating Margin-957.82%
Return on Equity-54.36%
Return on Assets-16.06%
Shares Outstanding5.73M
Shares Float4.65M
Beta1.59
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Ownership Breakdown

Institutions
7.75%
Insiders
12.66%
Retail / Other
79.59%

Top Institutional Holders

  • Yorkville Advisors Global, LP
    199.00K3.48%
  • AdvisorShares Investments, LLC
    102.79K1.80%
  • NATIONAL BANK OF CANADA /FI/
    5980.01%
  • SRS Capital Advisors Inc
    500.00%

Top Fund Holders

  • AdvisorShares Psychedelics ETF
    213.10K3.72%

Stock Splits

  • May 20, 20261:30